Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
- 1 May 2008
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 60 (2) , 200-207
- https://doi.org/10.1016/j.lungcan.2007.10.003
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Costs of initial, continuing and terminal care in US patients with recurrence following early breast cancerJournal of Clinical Oncology, 2005
- CAI Is a Potent Inhibitor of Neovascularization and Imparts Neuroprotection in a Mouse Model of Ischemic RetinopathyInvestigative Opthalmology & Visual Science, 2004
- CAI inhibits the growth of small cell lung cancer cellsLung Cancer, 2003
- Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell linesSurgery, 1997
- Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.Journal of Clinical Oncology, 1997
- Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrumentPublished by Elsevier ,1995
- Angiogenesis: role of calcium-mediated signal transduction.Proceedings of the National Academy of Sciences, 1995
- L651582: A Novel Antiproliferative and Antimetastasis AgentJNCI Journal of the National Cancer Institute, 1990
- Measuring the quality of life of cancer patientsJournal of Chronic Diseases, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958